このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Plus Therapeutics 将来の成長

Future 基準チェック /26

Plus Therapeuticsは、5.3%と61.6%でそれぞれ年率5.3%で利益と収益が成長すると予測される一方、EPSはgrowで26.5%年率。

主要情報

5.3%

収益成長率

26.5%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	61.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	01 Jun 2024

今後の成長に関する最新情報

Recent updates

Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating

Oct 07

Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end

Sep 22

Shareholders May Not Be So Generous With Plus Therapeutics, Inc.'s (NASDAQ:PSTV) CEO Compensation And Here's Why

May 11

Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract

May 04

業績と収益の成長予測

NasdaqCM:PSTV - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-50	N/A	-61	2
12/31/2025	3	-29	N/A	-28	3
12/31/2024	5	-15	N/A	-14	3
3/31/2024	6	-12	-12	-12	N/A
12/31/2023	5	-13	-13	-13	N/A
9/30/2023	4	-15	-13	-13	N/A
6/30/2023	3	-17	-15	-15	N/A
3/31/2023	1	-21	-15	-15	N/A
12/31/2022	0	-20	-14	-13	N/A
9/30/2022	0	-19	-14	-13	N/A
6/30/2022	N/A	-17	-12	-11	N/A
3/31/2022	N/A	-15	-12	-11	N/A
12/31/2021	N/A	-13	-10	-10	N/A
9/30/2021	N/A	-13	-11	-11	N/A
6/30/2021	N/A	-11	-11	-11	N/A
3/31/2021	0	-10	-11	-10	N/A
12/31/2020	0	-8	-9	-8	N/A
9/30/2020	1	-4	-5	-4	N/A
6/30/2020	6	-2	-5	-4	N/A
3/31/2020	6	-2	-4	-4	N/A
12/31/2019	7	-4	-6	-6	N/A
9/30/2019	7	-7	-9	-9	N/A
6/30/2019	2	-11	-10	-10	N/A
3/31/2019	2	-9	-11	-11	N/A
12/31/2018	3	-11	-12	-12	N/A
9/30/2018	4	-18	-14	-14	N/A
6/30/2018	5	-19	-15	-15	N/A
3/31/2018	6	-24	-18	-17	N/A
12/31/2017	6	-27	N/A	-18	N/A
9/30/2017	8	-23	N/A	-18	N/A
6/30/2017	9	-24	N/A	-19	N/A
3/31/2017	10	-24	N/A	-19	N/A
12/31/2016	11	-22	N/A	-20	N/A
9/30/2016	12	-20	N/A	-20	N/A
6/30/2016	12	-13	N/A	-21	N/A
3/31/2016	12	-2	N/A	-20	N/A
12/31/2015	12	-19	N/A	-20	N/A
9/30/2015	12	-24	N/A	-21	N/A
6/30/2015	11	-34	N/A	-22	N/A
3/31/2015	9	-51	N/A	-26	N/A
12/31/2014	8	-39	N/A	-30	N/A
9/30/2014	7	-42	N/A	-35	N/A
6/30/2014	9	-38	N/A	-36	N/A
3/31/2014	10	-29	N/A	-34	N/A
12/31/2013	12	-26	N/A	-35	N/A
9/30/2013	16	-20	N/A	-33	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PSTV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PSTV今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PSTV今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PSTVの収益 ( 61.6% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: PSTVの収益 ( 61.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PSTVの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Plus Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates increase by 104%

Price target increased by 50% to US$16.50

Consensus revenue estimates fall by 34%

Consensus revenue estimates fall by 28%

Consensus revenue estimates increase by 21%

Price target decreased by 13% to US$46.50

Recent updates

New major risk - Market cap size

Plus Therapeutics, Inc. Receives the Resignation of Dr. Norman Lafrance, Its Chief Medical Officer, Effective June 12, 2024

New minor risk - Share price stability

Consensus revenue estimates increase by 104%

Plus Therapeutics, Inc., Annual General Meeting, Aug 15, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations

Plus Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New major risk - Revenue and earnings growth

Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC

Plus Therapeutics, Inc. announced that it expects to receive $17.948504 million in funding from Aigh Capital Management, LLC

Price target increased by 50% to US$16.50

Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense

Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic

Plus Therapeutics Receives Non-Compliance Update from Nasdaq

Consensus revenue estimates fall by 34%

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Plus Therapeutics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Insufficient new directors

Plus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.9375 million.

Plus Therapeutics, Inc. has filed a Follow-on Equity Offering.

Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting

Consensus revenue estimates fall by 28%

New major risk - Shareholder dilution

Plus Therapeutics, Inc. (NasdaqCM:PSTV) announces an Equity Buyback for $0.5 million worth of its shares.

Plus Therapeutics, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Plus Therapeutics, Inc. Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

Plus Therapeutics, Inc. Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase

Consensus revenue estimates increase by 21%

Plus Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Plus Therapeutics, Inc. Appoints Pius Maliakal as Vice President of Clinical Operations

Plus Therapeutics, Inc. Reports Positive Interim Updates from Two Respect Clinical Trials at SNMMI Annual Meeting

Price target decreased by 13% to US$46.50

Consensus revenue estimates increase by 21%, EPS downgraded

Consensus revenue estimates increase by 111%

Consensus revenue estimates fall by 42%

Plus Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Plus Therapeutics, Inc. Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases

Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

Plus Therapeutics Receives Second Letter from Nasdaq Regarding Minimum Bid Price Requirement

Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials

High number of new and inexperienced directors

Consensus revenue estimates increase by 50%

Plus Therapeutics to Provide Update on Respect(Tm) Clinical Trials At the 27Th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Plus Therapeutics, Inc. Announces Selection of Rhenium (186Re) Obisbemeda as International Non-Proprietary Name for 186RNL

Plus Therapeutics, Inc. to Report Q3, 2022 Results on Oct 20, 2022

Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating

Plus Therapeutics, Inc. Receives Product Development Research Grant by the Cancer Prevention and Research Institute of Texas

Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end

Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022

Plus Therapeutics, Inc. Announces Summary of FDA Meeting

Plus Therapeutics, Inc. (NasdaqCM:PSTV) announces an Equity Buyback for $2 million worth of its shares.

Plus Therapeutics, Inc. Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

Price target decreased to US$3.67

Plus Therapeutics GAAP EPS of -$0.24 misses by $0.02

Plus Therapeutics, Inc. to Report Q2, 2022 Results on Jul 21, 2022

Plus Therapeutics Completes Enrollment of Cohort 1 Respect-Lm Phase 1/2A Trial

Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting

Plus Therapeutics Receives Non-Compliance Notice from the Nasdaq Stock Market

Price target decreased to US$4.83

Price target decreased to US$5.17

High number of new and inexperienced directors

Plus Therapeutics, Inc. to Report Q1, 2022 Results on Apr 21, 2022

Plus Therapeutics, Inc., Annual General Meeting, May 16, 2022

Plus Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Price target decreased to US$5.67

Plus Therapeutics CEO Dr. Marc Hedrick - Cancer's Hardest Problems

Does Plus Therapeutics (NASDAQ:PSTV) Have A Healthy Balance Sheet?

Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT-GBM Trial